Geographically, 37% of our sales in the second quarter were in the U.S. compare to 42% last year with 63% of our sales outside the U.S. compared to 58% last year. The reason for the change from last year is clearly due to Laprolan acquisition. Bottom-line, these results indicate that we are executing well in both our U.S. and international businesses.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

Rochester Medical Corporation Stock Upgraded (ROCM)

Rochester Medical Corporation's CEO Discusses Q3 2012 Results - Earnings Call Transcript

Rochester Medical Corporation's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Rochester Medical Corporation Stock Upgraded (ROCM)

Rochester Medical CEO Discusses F1Q2012 Results - Earnings Call Transcript